| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Tebipenem targets bacterial penicillin-binding proteins (PBPs), which are essential for cell wall synthesis. By inhibiting PBPs, tebipenem disrupts the cross-linking of peptidoglycan, the major structural component of the bacterial cell wall. This leads to cell wall weakening, osmotic instability, and ultimately bacterial cell death. The compound is a slow substrate that inhibits beta-lactamase from Mycobacterium tuberculosis.
|
|---|---|
| ln Vitro |
At low micromolar doses, terbipenem shows delayed tight-binding inhibition compared to the chromogenic substrate cefnidazole, with Km and kcat values of 0.8 μM and 0.03 min, respectively [1]. It has been demonstrated that terbipenem exhibits good effectiveness against B-producing Streptococcus pneumoniae. pseudomallei, with 2 mg/L MIC50 and MIC90 [2]. With a MIC value of ≤0.25 μg/mL, terbipenem exhibits good efficacy against Streptococcus pneumoniae[3].
In vitro, tebipenem shows delayed tight-binding inhibition compared to the chromogenic substrate cefnidazole, with Km and kcat values of 0.8 μM and 0.03 min⁻¹, respectively. It exhibits good effectiveness against B. pseudomallei, with MIC50 and MIC90 values of 2 mg/L. The compound shows good efficacy against Streptococcus pneumoniae with a MIC value of ≤0.25 μg/mL. |
| ln Vivo |
In vivo, tebipenem is effective against a broad range of bacterial infections. It has been demonstrated to exhibit good effectiveness against B. pseudomallei with MIC50 and MIC90 values of both 2 mg/L. As an orally available carbapenem, tebipenem offers the convenience of oral administration for the treatment of systemic infections, providing an alternative to intravenous carbapenem therapy.
|
| Enzyme Assay |
In vitro enzyme assays for tebipenem measure its inhibition of bacterial penicillin-binding proteins and beta-lactamase activity. The enzyme is incubated with chromogenic substrates and varying concentrations of the compound. Tebipenem shows delayed tight-binding inhibition with Km and kcat values of 0.8 μM and 0.03 min⁻¹, respectively. The compound's interaction with beta-lactamase from Mycobacterium tuberculosis has also been characterized.
|
| Cell Assay |
In vitro cell-based assays for tebipenem use bacterial cultures of susceptible strains. Minimum inhibitory concentrations (MIC) are determined using broth microdilution methods. The compound shows MIC50 and MIC90 of 2 mg/L against B. pseudomallei and MIC ≤0.25 μg/mL against Streptococcus pneumoniae. Broth microdilution assays follow CLSI guidelines for antimicrobial susceptibility testing.
|
| Animal Protocol |
In vivo animal models for tebipenem include mouse models of bacterial infection. Animals are infected with pathogenic bacteria and treated with tebipenem at various doses. Efficacy is evaluated by measuring bacterial load in target tissues, survival rates, and clinical signs of infection. Pharmacokinetic studies in rodents measure drug absorption, distribution, metabolism, and excretion following oral administration.
|
| ADME/Pharmacokinetics |
Tebipenem has a molecular formula of C16H21N3O4S2 and a molecular weight of 383.49. It has a logP of -1.71, indicating good aqueous solubility. The compound is orally bioavailable and is absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted via urine. The compound is stored as a solid at room temperature.
|
| Toxicity/Toxicokinetics |
Toxicity data for tebipenem are available from preclinical safety studies. As a carbapenem antibiotic, common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and potential for seizures at high doses. The compound is for research use only and not for human use. Appropriate safety precautions should be taken during handling.
|
| References |
[1]. Hazra S, et al. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry. 2014 Jun 10;53(22):3671-8
[2]. Seenama C, et al. In vitro activity of tebipenem against Burkholderia pseudomallei. Int J Antimicrob Agents. 2013 Oct;42(4):375. [3]. Li H, et al. In vitro antibacterial activities of two novel oral antibiotics, tebipenem and cefditoren, and other comparators against community-acquired respiratory tract infection-associated bacterial pathogens: A multicentre study in China. Int J Antimicrob Agents. 2014 Jan;43(1):92-3. |
| Additional Infomation |
Tebipenem is also known by the synonyms L-084, ME1211, and LJC 11036. It is an orally available carbapenem antibiotic that shows broad-spectrum activity against Gram-positive and Gram-negative bacteria, except for Pseudomonas aeruginosa. The compound has been studied in clinical trials for the treatment of bacterial infections. It is used primarily for research purposes.
|
| Molecular Formula |
C16H21N3O4S2
|
|---|---|
| Molecular Weight |
383.4856
|
| Exact Mass |
383.097
|
| CAS # |
161715-21-5
|
| Related CAS # |
Tebipenem pivoxil;161715-24-8;Tebipenem pivoxil hydrochloride;211558-19-9
|
| PubChem CID |
9800194
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
624.5±65.0 °C at 760 mmHg
|
| Flash Point |
331.5±34.3 °C
|
| Vapour Pressure |
0.0±4.1 mmHg at 25°C
|
| Index of Refraction |
1.826
|
| LogP |
-1.71
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
689
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
S(C1([H])C([H])([H])N(C2=NC([H])([H])C([H])([H])S2)C1([H])[H])C1=C(C(=O)O[H])N2C([C@]([H])([C@@]([H])(C([H])([H])[H])O[H])[C@@]2([H])[C@@]1([H])C([H])([H])[H])=O
|
| InChi Key |
GXXLUDOKHXEFBQ-YJFSRANCSA-N
|
| InChi Code |
InChI=1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1
|
| Chemical Name |
(4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~86.91 mM)
H2O : ~7.14 mg/mL (~18.62 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 8.33 mg/mL (21.72 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6076 mL | 13.0381 mL | 26.0763 mL | |
| 5 mM | 0.5215 mL | 2.6076 mL | 5.2153 mL | |
| 10 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
